INSR and hyperinsulinism: The tumor promoting effects of hyperinsulinemia were ameliorated by either lowering circulating insulin levels with a β3-adrenergic agonist (153), or with inhibitors of the IR/IGF-1R, PI3K, and/or mTOR (147, 154, 155).